DB
UTHR icon

Dmitry Balyasny’s United Therapeutics UTHR Stock Holding History

Dmitry Balyasny’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
+600
New +$338K ﹤0.01% 2684
2025
Q4 		– Sell
-32,500
Closed -$13.6M – 3587
2025
Q3 		$13.6M Buy
+32,500
New +$10.9M 0.02% 898
2022
Q3 		– Sell
-26,000
Closed -$6.13M – 3280
2022
Q2 		$6.13M Buy
+26,000
New +$5.29M 0.02% 850

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Dmitry Balyasny's UTHR Position: Q2 2026 in Review

Dmitry Balyasny reduced its United Therapeutics (UTHR) stake by 94% in Q2 2026, selling an estimated $19.3M and leaving 2,307 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Dmitry Balyasny first reported a position in UTHR in Q4 2015 and has held it in 23 quarters since. The position peaked at $61.6M in Q3 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Dmitry Balyasny held 2,307 shares of United Therapeutics worth $1.25M as of Q2 2026.
  • Dmitry Balyasny sold 34,316 United Therapeutics shares in Q2 2026, an estimated $19.3M.
  • United Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2090 holding.
  • Dmitry Balyasny first reported a position in United Therapeutics in Q4 2015 and has held it in 23 quarters since.
  • Dmitry Balyasny's United Therapeutics position peaked at $61.6M in Q3 2025.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.